Kinetin

Kinetin

SCHEMBL17847289

c1coc(CNc2[nH]cnc3ncnc2-3)c1.c1coc(CNc2ncnc3[nH]cnc23)c1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.53
TSHR P16473 5/20 0.53
KMT2A Q03164 3/20 0.53
HIF1A Q16665 2/20 0.53
MEN1 O00255 2/20 0.53
ALOX15 P16050 2/20 0.53
CYP1A2 P05177 2/20 0.53
TP53 P04637 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
KDR P35968 1/20 0.53
POLB P06746 4/20 0.47
CCNB2 O95067 2/20 0.46
CDK1 P06493 2/20 0.46
CCNB1 P14635 2/20 0.46
CCNB3 Q8WWL7 2/20 0.46
HTT P42858 7/20 0.44
RAB9A P51151 2/20 0.44
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
6-Benzylaminopurine SCHEMBL6864326 0.94 SMN1; SMN2 (0.47) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL2138115 0.89 SMN1; SMN2 (0.45) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL9776947 0.89 SMN1; SMN2 (0.42) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL458140 0.89 SMN1; SMN2 (0.54) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL23818 0.89 SMN1; SMN2 (0.54) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL584400 0.88 SMN1; SMN2 (0.53) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL9125232 0.88 SMN1; SMN2 (0.53) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL15705 0.88 SMN1; SMN2 (0.66) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL29829493 0.88 SMN1; SMN2 (0.66) SMN1; SMN2TSHRKMT2AHIF1AMEN1
Kinetin SCHEMBL893438 0.87 TSHR (0.43) SMN1; SMN2TSHRKMT2AHIF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233861-B1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL) PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) 2019-04-10 EP disclosed
US-10093675-B2 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2018-10-09 US disclosed
US-20170362236-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2017-12-21 US disclosed
EP-3233861-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS Ustav Experimentalni Botaniky Av CR, V.V.I. (CZ) 2017-10-25 EP disclosed
WO-2016095880-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362236-A1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL)PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS PNP, UNG, NUDT1 SMN1; SMN2 3293/4885TSHR 4432/4885KMT2A 3968/4885
US-10093675-B2 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications PNP, UNG, NUDT1 SMN1; SMN2 3293/4885TSHR 4432/4885KMT2A 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.